Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.36 |
| ▸ | KDM6B | O15054 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799283 | 0.90 | KDM4C (0.37) | KDM4CKDM6BALDH1A1NTRK1JAK2 | |
| SCHEMBL171942 | 0.80 | P2RX7 (0.39) | KDM4CKDM6BKDM4EALDH1A1GLA | |
| SCHEMBL14743451 | 0.66 | KDM4E (0.46) | KDM4CKDM6BKDM4EALDH1A1GLA | |
| SCHEMBL13086655 | 0.65 | KDM4C (0.45) | KDM4CKDM6BKDM4EALDH1A1GLA | |
| SCHEMBL798742 | 0.64 | KDM4C (0.42) | KDM4CKDM6BALDH1A1GAALMNA | |
| SCHEMBL172133 | 0.62 | RAB9A (0.44) | KDM4CKDM6BALDH1A1GAA | |
| SCHEMBL31294174 | 0.60 | HSD11B1 (0.54) | KDM4EALDH1A1GAALMNA | |
| SCHEMBL23880058 | 0.60 | SCN9A (0.48) | CNR2CNR1 | |
| SCHEMBL20687415 | 0.60 | TSHR (0.55) | KDM4EALDH1A1GAALMNA | |
| SCHEMBL20462813 | 0.60 | KDM4C (0.50) | KDM4CKDM6BKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | KDM4C 3079/4885KDM6B 2058/4885KDM4E 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.